You are here

lymphoma

Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi

Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi

Fierce Pharma

Bristol Myers Squibb

Flag link:

New study points to why CAR-T therapy may fail in some lymphoma patients

New study points to why CAR-T therapy may fail in some lymphoma patients

Fierce Biotech

Flag link:

FDA to decide on TG Therapeutics’ lymphoma drug early next year

FDA to decide on TG Therapeutics’ lymphoma drug early next year

Pharmaforum

TG Therapeutics

Bristol-Myers Squibb

Flag link:

Scopus Bio preps trials of gene-silencing immuno-oncology drug

Scopus Bio preps trials of gene-silencing immuno-oncology drug

Pharmaforum

Scopus BioPharma

immuno-oncology

Flag link:

ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma

ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma

Fierce Biotech

Flag link:

Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug

Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug

Xconomy

Flag link:

Servier acquires lymphoma drug Pixuvri from CTI BioPharma

Servier acquires lymphoma drug Pixuvri from CTI BioPharma

Pharmaceutical Business Review

Flag link:

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Yahoo/Reuters

Flag link:

TG aims for accelerated approval of lymphoma candidate

TG aims for accelerated approval of lymphoma candidate

BioCentury

TG Therapeutics

Flag link:

ESMO18: Merck’s STING agonist lacks bite on its own

ESMO18: Merck’s STING agonist lacks bite on its own

Fierce Biotech

Flag link:

AbbVie's stock falls after lymphoma treatment trial data disappoints

AbbVie's stock falls after lymphoma treatment trial data disappoints

Marketwatch

clinical trials

Flag link:

Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable

Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable

Forbes

cytokine release syndrome

Flag link:

Hemo-oncology newbie Bayer gears up for copanlisib launch

Hemo-oncology newbie Bayer gears up for copanlisib launch

Fierce Pharma

Flag link:

Two cancer drug prices have already been hiked by 8% this year

Two cancer drug prices have already been hiked by 8% this year

Marketwatch

Teva Pharmaceutical

Flag link:

Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep

Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep

Endpoints

clinical trials

Flag link:

Novartis' CAR-T stacks up to Kite in lymphoma

Novartis' CAR-T stacks up to Kite in lymphoma

BioPharma Dive

Flag link:

Celldex Cancer Drug Shows Good Early Data

Celldex Cancer Drug Shows Good Early Data

Investopedia

Celldex Therapeutics

Flag link:

Seattle Genetics moves up FDA timeline for cash cow drug Adcetris

Seattle Genetics moves up FDA timeline for cash cow drug Adcetris

Bizjournals.com

Seattle Genetics

Flag link:

Glimpse of promising lymphoma responses spurs a sharp spike in Epizyme shares

Glimpse of promising lymphoma responses spurs a sharp spike in Epizyme shares

Fierce Biotech

Flag link:

JNJ launches PhII lymphoma study for daratumumab

JNJ launches PhII lymphoma study for daratumumab

Fierce Biotech

non-Hodgkin's lymphoma

Flag link:

Pages